As a little gift ahead of Independence Day (for those in the U.S.), Rishikesh Kayathi and I gladly share some additional insights from our latest NGS DxBook report, this time focusing on the competitive landscape of sample prep vendors in the clinical oncology. Here are some highlights:
- Labs offering 2 panels leverage a variety of sample prep vendors to meet their specific needs, demonstrating the ability of sample prep vendors to continue to differentiate to meet specific downstream needs (and customers to seek independence from the monarchy!) :)
- Smaller sample prep vendors shine in specialized segments, providing unique and differentiated products across various panel types, including solid tumors and liquid biopsies. We celebrate this entrepreneurial spirit on Independence Day (too much?)
- The sample prep market is ripe for growth! Vendors that deliver accurate, robust, and cost-effective assays can significantly penetrate the market. Early engagement and involvement in lab workflows are critical to success. (I’m pretty sure this is what the founding fathers envisioned)
·- Large-scale providers and academic medical centers often use custom solutions ("homebrew") for flexibility, while most decentralized labs opt for off-the-shelf kits with minimal customization. (Feel free to come up with your own analogy here).
As usual, feel free to ping us if you’d like to discuss this post / data (or others) in more detail! Happy 4th!
#NGSisUnstoppable, #Illumina, #ThermoFisher #IDTdna, #Roche, #Agilent, #Qiagen, #SophiaGenetics, #OncoDNA,
#TwistBioScience, #Pillar
